Tumor immunotherapy research prosci Lag3 antibody solution

LAG-3 It's a kind of Ⅰ Type I transmembrane protein , There are four Ig Like domain （D1-D4）.LAG-3 Of D1 from 9 strip β- Chain composition , They are called A、B、C、C'、C”、D、E、F and G chain . about 30 The additional sequence of amino acids is located in C and C' Between chains , Form a ring , be called “ Extra ring ”. Although the sequence similarity is low , But in humans and mice LAG-3 This ring can be observed in , It is reported that this ring participated in LAG-3 And major histocompatibility complexes II class （MHCII） Relationship between . Besides ,LAG-3 Highly glycosylated , stay D2-D4 There are multiple N- Glycosylation sites .Galectin-3 And hepatic sinusoidal endothelial cell lectin （LSECtin） Considered to be related to LAG-3 Glycans interact .

LAG-3 Of D4 And the transmembrane region has a long amino acid sequence called “ Linker peptide ”. Based on mouse model , Found metalloproteinases ADAM10 and ADAM17 Can be in CP Crack at LAG-3, And release in soluble form LAG-3 Extracellular region . therefore ,ADAM10 and ADAM17 Probably by regulating the cell surface LAG-3 To adjust the quantity LAG-3 Inhibition of .

LAG-3 Immunosuppressive effect   

all the time , In tumor LAG-3 Expression level and LAG-3+ Cell infiltration and tumor progression 、 Poor prognosis is associated with various types of human tumors . These results strongly suggest that ,LAG-3 Participated in similar PD-1 Tumor immune escape mechanism .

However ,LAG-3 The exact signal path of is still unknown . Have proved ,LAG-3 The inhibitory effect of is not caused by CD4 Competitive combination pMHC II Caused by the . According to a research report ,LAG-3 It may be through FXXL Motif and C- At the end EX-repeat Synergistic induction inhibition mechanism . Knocking out EX Repeat sequence or in FXXL When inducing mutations in the sequence ,LAG-3 The inhibitory effect of disappeared .LAG-3 How it interacts with intracellular signaling proteins , There are still many unknowns .

AI Meijie ProSci LAG3 Antibodies are designed to improve in vitro research . Unlike antibodies developed using proteins made in yeast or bacteria , these LAG-3 Antibodies are developed using antigens expressed in mammalian cell lines , Post translational modification of natural proteins . It can be applied to application types that have been tested and verified .

AI Meijie ProSci LAG3 antibody Application instructions ：

Can be used for  ELISA, The initial concentration is  0.25 μg/mL. For Western blotting , The initial concentration is  0.25 μg/mL. For immunocytochemistry , from  1 μg/mL  Start . For immunofluorescence , from  10 μg/mL  Start . For immunohistochemistry , from  5 μg/mL  Start . For flow cytometry , from  1 μg/ml  Start .

AI Meijie ProSci LAG3 Antibody validation ：

Western blotting in human samples ; Immunohistochemistry in human samples ; Immunocytochemistry in human samples ; Immunofluorescence in human samples and flow cytometry in human samples . All other applications and species have not been tested .

LAG3 antibody Citations ：

1:Huard B, Tournier M, Hercend T, et al. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol 1994; 24:3216–21.

2:Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003; 24:619–22.

3:Workman CJ, Wang Y, El Kasmi KC, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol. 2009; 182:1885–91.

4:Workman CJ, Vignali DA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol 2003; 33:970–9.